摘要
目的:评价国产司帕沙星口服治疗急性细菌感染的临床疗效和安全性。方法:计算机检索国内1993~2009年有关国产司帕沙星治疗急性细菌感染的文献,并逐个进行质量评价和资料提取,用RevMan4.2.2软件进行Meta分析。结果:共有10项随机对照试验符合纳入标准。试验组使用司帕沙星,对照组使用其它氟喹诺酮类药物。试验组和对照组的临床痊愈率、临床有效率、细菌清除率和安全性比较均具有同质性。2组的临床痊愈率、临床有效率和细菌清除率的合并效应量的估计比较,差异有统计学意义(P<0.05),而安全性比较差异无统计学意义(P>0.05)。结论:现有的临床研究证据表明,国产司帕沙星口服治疗急性细菌感染的临床疗效较好,不良反应的发生率较低。
OBJECTIVE:To assess the clinical efficacy and safety of domestic sparfloxacin for acute bacterial infections.METHODS:Domestic literatures about sparfloxacin for acute bacterial infections were retrieved by computer and their quality was evaluated to extract data(1993~2009).RevMan 4.2.2 software was used for Meta-analysis.RESULTS:A total of 10 RCT were enrolled.The comparisons of 2 groups were homogeneous in terms of clinical cure rate,clinical response rate,bacterial clearance rate and safety.There was statistical significance in comparison of combined effect variable between 2 groups in respect of cure rate,response rate and bacterial clearance rate(P0.05).But the comparison of clinical safety had no statistical significance(P0.05).CONCLUSION:The currently available evidence shows that clinical efficacy of domestic sparfloxacin for acute bacterial infections is better and incidence of ADR was lower.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第20期1902-1905,共4页
China Pharmacy
关键词
司帕沙星
急性细菌感染
随机对照试验
META分析
Sparfloxacin
Acute bacterial infections
Randomized controlled trials
Meta-analysis